Navigation Links
GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting

in the Phase III ADT clinical trial.

-- "Prevalence of osteoporosis and osteopenia during androgen deprivation therapy (ADT) for prostate cancer: Baseline data from a large randomized controlled trial." Poster number: F5. Abstract number: 5116.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

About GTx

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for cancer cachexia in non-small cell lung cancer patients in June of 2007. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic kidney disease muscle wasting by the end of 2007. GTx believes that Ostarine(TM) also has the potential to treat a variety of other indications associated with muscle wasting and bone loss including sarcopenia and osteoporosis.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertaint
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/29/2014)... July 29, 2014 Apex Medical Corporation (Apex, TWSE: ... Area Care sectors, announces that it is appealing the judgment ... in Germany that found the headgear ... that it has initiated invalidity challenges against various ResMed patents ... counterattacking against trivial and junk patents. ResMed ...
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 /PRNewswire/ ... of Nancy Thornberry to its board ... and franchise head, Diabetes and Endocrinology for Merck ... research, strategy and overall pipeline management in diabetes, ... scientist, initiated and co-led the program that resulted ...
(Date:7/29/2014)... July 29, 2014  Encision Inc. (OTCQB:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... June 30, 2014. The Company posted quarterly ... loss of $202 thousand, or $(0.02) per share. These ... a net loss of $311 thousand, or $(0.04) per ...
Breaking Medicine Technology:Apex Continues Fighting Against Patents to Free Up Competition 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4
... CHENGDU, China , May 7 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... and sells modernized traditional Chinese medicine,("TCM") and branded generics based in ... call to discuss its fiscal 2010 third,quarter results at 9:00 a.m. ... , , ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today announced its fiscal 2010 third quarter ... on May 6, 2010 , and is payable on June 30, 2010 , to ... , , ... , Hill-Rom is a leading ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET 2Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET 3
(Date:7/29/2014)... Mach7 Technologies, an award-winning provider of ... of an enhanced version of its Physician & ... & Patient Portal enables direct communication and collaboration ... a comprehensive view of their care history, including ... care records and intelligently delivers access to records ...
(Date:7/29/2014)... Jessup, PA (PRWEB) July 29, 2014 ... Business Process Outsourcing solutions for health plans in ... and Managed Medicaid markets recently held its annual ... Jessup, Pa. Under the conference theme, “Partners in ... convened management executives and operations leaders from TMG ...
(Date:7/29/2014)... assistant professors at the Virginia Tech Carilion Research ... Commonwealth Health Research Board to investigate hereditary breast ... approaches. , The board funds research intended to benefit ... project to study the mechanisms behind hereditary breast cancer ... often has a poor outcome, especially in Virginians compared ...
(Date:7/29/2014)... On Friday, the United States Senate ... of October 12-18, 2014, as "National Case Management Week" ... healthcare outcomes for patients. The resolution was introduced by ... with support by the Case Management Society of America ... management professionals for their contributions to healthcare. , “Case ...
(Date:7/29/2014)... 2014 “Approximately 18% of our population ... common chronic illnesses,” Western Washington Medical Group says in ... for those suffering from allergies to seek medical attention. ... care each year in the United States,” they continue. ... of life for themselves, rather than seeking the appropriate ...
Breaking Medicine News(10 mins):Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 2Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 3Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3Health News:Scientists to study hereditary breast cancer to find BRCA1 treatment 2Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3
... 26 ( www.amdl.com ) China continues to show ... Inc. (NYSE Alternext US: ADL) Chairman and CEO Mr. ... of an internal economic forecast research report indicating China ... the world, eclipsing every other international market.Mr. MacLellan has ...
... NEW YORK, Jan. 26 The National Center on ... announced today that Bruce E. Mosler has been ... ) , Mosler, president and CEO of Cushman ... estate services firm and serves on its board of ...
... hard work and dedication to the highest quality of care ... ... 26, 2009 -- Sierra Tucson, a premier treatment center dedicated ... disorders, today announced the achievement of accreditation as a "Hospital" ...
... LOUIS, Jan. 26 KV Pharmaceutical,(NYSE: KVa/KVb) has voluntarily suspended ... certain products that it distributes but does,not manufacture. The ... Additionally, the company will conduct a voluntary recall of ... recall are currently under discussion,with the U.S. Food and Drug ...
... Mass., Jan. 26 Instrumentation Laboratory (IL) today ... its contract to offer IL,s critical care portfolio ... history between the two companies, whose original contract ... of critical care analyzers, reagents, consumables and service, ...
... Medimetriks Pharmaceuticals announced today that the Company has ... PRGO ), a leading manufacturer in the ... Distributor of generic versions of Medimetriks, branded products in ... receive a percentage of Perrigo,s Net Sales on the ...
Cached Medicine News:Health News:AMDL, Inc. Chairman & CEO Announces Expert Opinion on China's Economic Forecast 2Health News:Bruce E. Mosler, President and CEO of Cushman & Wakefield Elected to CASA* Board 2Health News:Bruce E. Mosler, President and CEO of Cushman & Wakefield Elected to CASA* Board 3Health News:Sierra Tucson Achieves Hospital Accreditation, Now Holds Dual Accreditation by the Joint Commission 2Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 2Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 3Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 4Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 5Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 2Health News:Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio 3Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 2Health News:Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals 3
... Used for catheter or instrument ... features a fabrication process that eliminates ... and introducer dilator, facilitating introduction through ... reinforcement sleeve prevents movement between introducer ...
... Used for temporary internal ... junction to the bladder. ... packages. Intended for one-time ... is advised; C-Flex® and ...
... or instrument introduction. The dual knobs ... away and removed. The maximum diameter ... be introduced should be measured to ... Supplied sterile in peel-open packages. Intended ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: